Previous studies have already reported that PCa patients with MDH2 overexpression have a significantly shorter period of relapse-free survival, and that stable knockdown of MDH2 PCa cell lines decreased cell proliferation and increased docetaxel sensitivity, all suggesting that MDH2 inhibition could be a viable strategy to target CRPC [131]. The gene discussed is MDH2; the disease is posterior cortical atrophy.